Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial ...

Vascepa, approved in the U.S. to reduce triglycerides and cardiovascular events, helped Amarin generate $285.3M in net product revenue in 2023, a ~22% YoY decline from a year ago. More on Amarin ...

Amarin first introduced its drug in the US as ... how the UK will be prioritising access to local health economies." Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe ...

Amarin said Peter Fishman has been appointed its new finance chief, effective immediately. The company said Fishman most recently served as its global controller and principal financial and ...

He will be responsible for leading Amarin’s global finance organization and will report directly to the Company’s Chief Executive Officer, Aaron Berg. Most recently, Mr. F Amarin (AMRN ...

The decliners from the UK and Ireland were led by biopharmaceutical company Amarin (AMRN) and pharmaceutical company Avadel Pharmaceuticals (AVDL), which lost nearly 2% and 1.3% respectively.